• Angiotensin (1-7): Mechanistic Power and Translational Visio

  2026-07-28

  This thought-leadership article explores the multifaceted roles of Angiotensin (1-7)—the endogenous heptapeptide Asp-Arg-Val-Tyr-Ile-His-Pro—in modulating disease-relevant pathways, translating mechanistic insights into experimental strategies, and positioning researchers at the leading edge of anti-fibrotic and anti-inflammatory innovation. Uniting evidence from microbial RAS modulation, advanced cell assay techniques, and translational research, the article provides actionable guidance, protocol parameters, and a critical outlook on the future of Ang-(1-7) in both bench and preclinical contexts.

• OTUD3 Stabilizes SLC7A11 and Drives Sunitinib Resistance in

  2026-07-28

  This article reviews a 2025 study revealing that OTUD3 overexpression stabilizes the cystine transporter SLC7A11, thereby suppressing ferroptosis and promoting sunitinib resistance in clear cell renal cell carcinoma (ccRCC). The findings highlight a targetable mechanism underlying therapy resistance, with implications for designing strategies to sensitize ccRCC to ferroptosis-inducing treatments.

• Strategic Use of A-769662: AMPK Activation Beyond Old Dogma

  2026-07-27

  This article redefines the mechanistic and translational landscape of AMPK activation, spotlighting A-769662 as an advanced research tool for metabolism, autophagy, and metabolic disease. By integrating recent paradigm-shifting findings and best-practice guidance, it positions translational scientists to design experiments that reflect the dualistic role of AMPK, leveraging APExBIO’s A-769662 for reliable, hypothesis-driven discoveries.

• Anlotinib Hydrochloride: Translational Advances in Multi-Tar

  2026-07-27

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, is reshaping experimental cancer research through advanced anti-angiogenic strategies. This article bridges mechanistic insight with translational relevance, offering assay guidance and practical perspectives beyond existing resources.

• Gepotidacin: Mechanistic Innovation and Translational Impact

  2026-07-26

  This thought-leadership article explores how Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor, is redefining antibacterial research. By integrating mechanistic insights, contemporary workflow strategies, and competitive clinical perspectives, we chart a path for translational researchers confronting the urgent challenges of antibiotic resistance and multidrug-resistant pathogens.

• Apigenin: Advancing HDAC Inhibition and Neuro-Oncology Resea

  2026-07-25

  Explore the unique dual role of Apigenin in malignant mesothelioma growth inhibition and neurodegeneration research. This article delves into mechanistic insights, protocol design, and how network medicine advances practical assay decisions.

• Biotin-HPDP in Immune Checkpoint Research: Precision Protein

  2026-07-24

  Discover how Biotin-HPDP enables precision biotinylation of thiol groups in advanced protein studies, with a spotlight on immune checkpoint regulation and PD-L1 pathway analysis. This article reveals unique assay strategies and critical insights for translational immunology.

• Muscle-Derived BDNF and MMPs Direct Early Synaptic Assembly

  2026-07-24

  This study reveals how spatially localized, muscle-generated BDNF—regulated by calcium-dependent vesicular trafficking and proteolytic processing—controls the initial assembly of postsynaptic acetylcholine receptor clusters at vertebrate neuromuscular junctions. The findings clarify the intersection of muscle-derived BDNF signaling and extracellular matrix metalloproteinase (MMP) activity, providing a mechanistic foundation for manipulating synaptic development in vitro and in vivo.

• Aurora Kinase A Overexpression in Retinoblastoma: Implicatio

  2026-07-23

  This study establishes Aurora kinase A (AURKA) as markedly overexpressed in human retinoblastoma, strongly correlating with key histopathologic high-risk features and poor response to chemotherapy. The findings provide a robust rationale for targeted AURKA inhibition as a therapeutic strategy in high-risk or chemoresistant retinoblastoma.

• WM-8014: Precision KAT6A Inhibitor for Epigenetic Research

  2026-07-23

  WM-8014 sets a new benchmark for selective KAT6A inhibition in cancer and epigenetic research, empowering robust oncogene-induced senescence and cell cycle arrest assays. Its reversible, competitive mechanism and nanomolar potency enable reproducible, mechanistically informed workflows—making it a trusted choice for translational studies.

• Stromal-Targeted Nanomedicine for Pancreatic Tumor Regressio

  2026-07-22

  This study introduces a multistage, acid-responsive nanomedicine that restores stromal homeostasis and enhances gemcitabine efficacy in pancreatic ductal adenocarcinoma (PDAC). The sequential release strategy addresses major barriers in drug delivery, showing significant tumor regression and offering new directions for overcoming chemoresistance.

• Molluscicidal Potential of Hagenia abyssinica: Field and Tox

  2026-07-22

  This study presents the first small-scale field validation of Hagenia abyssinica flower extracts as plant-based molluscicides against Biomphalaria snail species, a key vector in schistosomiasis transmission. The work highlights both efficacy and ecological safety challenges, offering new evidence for sustainable snail control strategies.

• Perphenazine in Research: Beyond D2 Antagonism to Host-Direc

  2026-07-21

  Explore the multifaceted research applications of Perphenazine—a dopamine D2 receptor antagonist—spanning neuropharmacology, cell death induction, and groundbreaking host-directed antibacterial strategies. Discover new mechanistic insights and practical protocols that set this article apart.

• (S)-(+)-Dimethindene maleate: Selective M2 Antagonist Protoc

  2026-07-21

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic receptor antagonist and H1 histamine receptor blocker, providing researchers with a reproducible tool for dissecting muscarinic acetylcholine receptor signaling in autonomic regulation, cardiovascular physiology, and respiratory function studies. It is best suited for in vitro and ex vivo workflows where precise receptor selectivity is required. This compound should not be used in diagnostic or therapeutic contexts.

• Ferrocenyl Novobiocin Derivatives: Synthesis and Bioactivity

  2026-07-20

  The referenced study presents a focused synthesis of novel ferrocenyl and organic novobiocin derivatives, evaluating their in vitro efficacy against Plasmodium falciparum and human breast cancer cells. By integrating a ferrocene moiety into the novobiocin scaffold, the research reveals notable enhancements in bioactivity, offering a promising avenue for combating drug resistance in infectious and oncological diseases.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page